<DOC>
	<DOCNO>NCT00896480</DOCNO>
	<brief_summary>The clinical objective clinical trial examine clinical activity term tumor response time treatment failure immunotherapeutic product GSK2132231A give patient unresectable progressive metastatic cutaneous melanoma . The safety treatment also assess immunogenicity term humoral cellular immune response induce GSK2132231A immunotherapeutic . Translational research objectives assess effect study treatment term various biological variable .</brief_summary>
	<brief_title>Study GSK2132231A Antigen-Specific Cancer Immunotherapeutic Patients With Inoperable Metastatic Cutaneous Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . The patient ( male female ) histologically proven , measurable metastatic cutaneous melanoma one following stage accord American Joint Committee Cancer classification 2002 : Stage III transit , Stage III unresectable , Stage IV M1a . 2 . There documented progression patient 's disease within 12 week first administration study treatment . 3 . The patient present screen least 3 tumor lesion diameter &gt; = 0.5 mm . 4 . Written inform consent obtain patient performance protocolspecific procedure . 5 . The patient &gt; = 18 year age time signature inform consent . 6 . The patient 's tumor show expression MAGEA3 gene least one two tumor biopsy perform baseline . 7 . The patient 's ECOG performance status 0 1 . 8 . The patient normal organ function , assessed standard laboratory criterion . 9 . If patient female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior administration study treatment , negative pregnancy test continue precaution entire study treatment period 2 month completion treatment injection series . 10 . In view investigator , patient comply requirement protocol . 1 . The patient time receive systemic ( bio ) chemotherapy 2 . The patient schedule receive anticancer specific treatment , include radiotherapy , immunotherapy , chemotherapy immunomodulating agent . 3 . The patient require concomitant treatment systemic corticosteroid , immunosuppressive agent . 4 . The patient receive cancer immunotherapeutic contain MAGE A3 antigen cancer immunotherapeutic his/her metastatic disease . 5 . Use investigational nonregistered product ( drug vaccine ) study treatment within 30 day precede first dose study treatment , plan use study period . 6 . The patient ( ) previous concomitant malignancy site , except effectively treat malignancy consider investigator highly likely cure . 7 . History allergic disease reaction likely exacerbate component study investigational product . 8 . The patient autoimmune disease , limited , neuroinflammatory autoimmune disease , systemic lupus erythematosus , inflammatory bowel disease 9 . The patient family history congenital hereditary immunodeficiency . 10 . The patient know positive human immunodeficiency virus ( HIV ) . 11 . The patient psychiatric addictive disorder may compromise his/her ability give inform consent , comply study procedure . 12 . The patient concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk . 13 . For female patient : patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>ASCI ( Antigen-Specific Cancer Immunotherapeutic )</keyword>
	<keyword>Cancer immunotherapeutic</keyword>
	<keyword>Malignant melanoma</keyword>
	<keyword>MAGE-A3</keyword>
</DOC>